Cartalax: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 6 sources cited

Overview

Cartalax is a Khavinson bioregulator tripeptide (Ala-Glu-Asp) targeting cartilage tissue and the musculoskeletal system. In cell culture studies it raised expression of cartilage matrix genes in aging human stem cells and normalized senescence markers in chondrocytes; effects on joint cartilage in people have not been shown in published trials. Used in Russian gerontological protocols to maintain joint integrity and counter age-related cartilage degeneration, it represents the bioregulatory approach to joint health.

Mechanism of Action

Cartalax is proposed to modulate gene expression in chondrocytes by interacting with tissue-specific chromatin regions. In aging cultures of human mesenchymal stem cells it increased gene expression and protein synthesis of SOX9, type II collagen, aggrecan, and cartilage oligomeric matrix protein (COMP). An effect on matrix metalloproteinases such as MMP-13 or their tissue inhibitors (TIMPs) in cartilage has not been reported; the one MMP finding is for MMP-9 in aging rat skin fibroblasts. Additionally, in cultured chondrocytes Cartalax normalized senescence-associated molecules (p16, p21, p53, TNF-α, IL-1α, Sirt1), helping maintain the regenerative potential that declines with age.

Cartalax Benefits: What the Research Shows

  • A study from the developers' group showed the AED peptide at 200 ng/ml activated gene expression and protein synthesis of chondrogenic markers (SOX9, aggrecan, type II collagen, COMP) in aging cultures of human mesenchymal stem cells (Advances in Gerontology, 2023).
  • Normalized the synthesis of senescence-associated molecules (p16, p21, p53, TNF-α, IL-1α, Sirt1) in aging cultured chondrocytes (Advances in Gerontology, 2023).
  • Short peptides (2–4 amino acids) have been reported to bind specific DNA sequences in fluorescence-quenching experiments and molecular modeling; confirmation by EMSA or ChIP assays was not found in the published work.
  • The AED peptide is a component of a cartilage polypeptide complex that the developers report is in phase 2 trials for osteoarthritis in Russia; no clinical safety data for Cartalax itself are indexed in PubMed.
  • A 2023 review by the developers states that the AED tripeptide was effective in animal models of osteoarthritis and when given orally to older patients with osteoarthritis; the underlying studies are not indexed in PubMed.

Cartalax Dosage

  • Standard dose: 10 mg subcutaneous injection daily.
  • Typical cycle: 10–20 days.
  • Repeat every 3–6 months for ongoing joint health maintenance.
  • Often combined with BPC-157 for enhanced joint and connective tissue healing — Cartalax provides epigenetic cartilage support while BPC-157 provides growth factor and angiogenic support.
  • Can be part of a comprehensive musculoskeletal bioregulator protocol alongside other tissue-specific peptides.
  • No food timing restrictions. Inject subcutaneously in the abdomen or thigh.
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Cartalax Side Effects & Safety

Known Side Effects

  • Injection site reactions — mild and uncommon.
  • The published literature on Cartalax is cell-culture work and reviews; it contains no human adverse-event data.
  • Systemic side effects have not been studied in humans.
  • Short treatment cycles minimize any theoretical risks.
  • Interactions with joint health supplements (glucosamine, chondroitin) or NSAIDs have not been studied.

Safety Profile

Cartalax's safety in humans has not been established. The published work on the AED peptide consists of cell-culture studies and reviews from the developers' group; no toxicology, pharmacokinetic, immunogenicity or clinical safety study is indexed in PubMed, so claims of decades of safe clinical use cannot be checked. Interactions with NSAIDs, corticosteroids, or other joint-related medications have not been studied. Contraindications are limited to known hypersensitivity and pregnancy/breastfeeding.

What to Expect

Days 1–10: No immediate subjective effects. Gene expression effects have been shown in cell cultures; they have not been measured in people. Days 11–20: The bioregulatory reset is establishing. Joint improvements are not typically perceptible during the treatment cycle itself. Weeks 3–12 (post-cycle): Benefits emerge gradually over the weeks following the cycle. Users may notice improved joint comfort, reduced morning stiffness, and better exercise tolerance. These reports are anecdotal; no published trial has measured joint symptoms or cartilage with Cartalax. Months 3–6: Effects persist for the inter-cycle period. Repeat cycles every 3–6 months maintain the benefits and provide cumulative improvement over multiple cycles.

Common Stacks

Storage & Handling

Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution, refrigerate and use within 20 days. Unreconstituted powder shelf life: 24 months. Oral capsules: store at room temperature.

Pricing & Available Variants

$55price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

Related Peptides

Track Cartalax in Your Protocol

Log your Cartalax doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free